Asthma Attack Treatment

Parents Sue After Son’s Asthma Death Following Inhaler Price Surge

The death of 22-year-old Cole Schmidtknecht highlights a critical flaw in the US healthcare system. His asthma medication, Advair Diskus, experienced a drastic price increase due to Pharmacy Benefit Managers (PBMs) manipulating formularies to maximize profits. This resulted in Cole lacking preventative medication, leading to a fatal asthma attack. His parents are now suing OptumRx and Walgreens, advocating for legislation requiring advanced notice of formulary changes and increased transparency within the PBM system. The Schmidtknechts’ tragedy underscores the urgent need for reform to prevent similar preventable deaths.

News

New Asthma Treatment: Hype vs. Reality—Expensive Injections, Limited Access

Research from King’s College London reveals benralizumab, an injectable drug already used for severe cases, as the first new asthma attack treatment in 50 years. Targeting eosinophils, a type of white blood cell contributing to lung inflammation, the therapy significantly reduced treatment failure rates compared to steroids (45% vs. 74%) in a 158-person trial. This new approach offers improved symptoms, quality of life, and reduced hospitalizations, potentially impacting the two million asthma attacks annually in the UK. While further large-scale trials are needed, the findings suggest a potential “game-changer” in asthma and COPD treatment.

John Q. Hosedrinker Nov 28, 2024

Asthma Attack Treatment

Parents Sue After Son’s Asthma Death Following Inhaler Price Surge

New Asthma Treatment: Hype vs. Reality—Expensive Injections, Limited Access

Stories You May Have Missed

Trump Admin Removes MLK Day, Juneteenth From National Park Fee-Free Days

French Navy Fires at Drones Near Nuclear Submarine Base

Supreme Court to Hear Case Challenging Birthright Citizenship, Sparking Fears of Constitutional Overturn

Hegseth Lied About Caribbean Boat Bombing Justification, Video Shows